Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 3

Status

Recruiting 6Active not recruiting 4Completed 3Withdrawn 2

Sponsor Class

INDUSTRY 6OTHER_GOV 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Levoleucovorin × Clear all
NCT06662786 2026-06-05

OrigAMI-2

Janssen Research & Development, LLC

Phase 3 Recruiting
1,000 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-06-05

OrigAMI-3

Janssen Research & Development, LLC

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06780111 2026-03-31

MK-3475-06E

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
298 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06428409 2026-01-22

MK-9999-02A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡